The researchers hope to reproduce in a prospective clinical trial the model's 70 percent to 80 percent accuracy for predicting immunotherapy response.
The firm hopes to establish a role for cancer vaccines as a tumor shrinking therapy, not just a tumor preventing therapy.
The firm's lead candidate targeting DHX9 has shown preclinical activity in MSI-high cancers and is steadily progressing toward the clinic.
Blincyto sales continue to grow following positive data last year in acute lymphoblastic leukemia and an update to NCCN guidelines for pediatric patients.
Sales of Keytruda surged as the company advances the drug to earlier lines of therapy while looking ahead to combination therapy opportunities.
Tumor agnostic trials of Enhertu and two investigational ADCs suggest that targeting HER2 could be a successful strategy across a range of solid tumors.
Patients with cancers of unknown primary had more treatment options and better outcomes when care was informed by a 90-gene expression assay.
At ESMO, researchers described their experience using a streamlined pathway to facilitate pretest education and deliver test results to breast cancer patients.
Treatment-naïve NSCLC patients with EGFR exon 20 insertion mutations had better median progression-free survival on the regimen compared to chemo alone.
Patients who had Opdivo or Keytruda added to standard neoadjuvant and adjuvant therapy had significantly higher rates of pathologic complete response.